Corline Biomedical AB (CLBIO.ST)

10.55 0.00 (0.00%) As of 11:25AM CEST. Market open.

Corline Biomedical AB

Lefflersgatan 5
Uppsala 754 50
Sweden
46 18 71 30 90
https://www.corline.se

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 13

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Henrik Nittmar Ph.D.	Chief Executive Officer	N/A	N/A	1966
Prof. Gunnar Tufveson	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company's products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; and CHC, which is used for the treatment of soft tissue injuries. The company was incorporated in 1991 and is based in Uppsala, Sweden.

Corporate governance

Corline Biomedical AB’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.